Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) has signed exclusive distribution agreements with CardiRad for the Nordics region and Femto Trade for Egypt.
CardiRad is a prominent distributor of innovative medical technologies in the Nordics, renowned for its strong expertise and extensive network in the fields of oncology and nuclear medicine. With this strategic agreement, CardiRad will be at the forefront of bringing OncoSil’s breakthrough technology to patients in Sweden, Denmark, Norway, and Finland, further enhancing cancer treatment capabilities in the region.
Femto Trade is a leading distributor of medical solutions in Egypt, specialising in nuclear medicine and interventional oncology. Its deep market reach, clinical knowledge, and established relationships with key medical institutions make them a valuable partner in delivering OncoSil’s transformative therapies to Egyptian patients.
Nigel Lange, CEO and Managing Director of OncoSil Medical, said the agreements reflect the company’s dedication to expanding access to its innovative brachytherapy treatment on a global scale.
“These partnerships mark an important step in our mission to provide life-changing care solutions to patients worldwide."